Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05EBY
|
|||
| Former ID |
DIB008329
|
|||
| Drug Name |
PCSK9 Adnectin
|
|||
| Synonyms |
PCSK9 Adnectin (cardiovascular); Adnectin program (cardiovascular disease), Adnexus/BMS; PCSK9 Adnectin (cardiovascular), Bristol-Myers Squibb
Click to Show/Hide
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Phase 1 | [1] | |
| Company |
Bristol-myers squibb
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | Target Info | Modulator | [2] |
| WikiPathways | PCSK9-mediated LDLR degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cholesterol-lowering blockbuster candidates speed into Phase III trials. Nat Rev Drug Discov. 2012 Nov;11(11):817-9. | |||
| REF 2 | Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J Pharmacol Exp Ther. 2014 Aug;350(2):412-24. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.